State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Cancer Med. 2022 Sep;11(18):3437-3444. doi: 10.1002/cam4.4705. Epub 2022 Mar 30.
Studies are trying to add immunotherapy to gemcitabine and cisplatin (GP) induction chemotherapy, the standard therapy, in nasopharyngeal carcinoma (NPC) patients with locoregionally advanced disease. However, how the immune system responds to GP remains unknown.
We examined the dynamic changes of circulating immune cells and plasma cytokines in NPC patients administered with GP.
After GP administration, immunosuppressive myeloid cells, including CD11b+CD14+ monocytes, CD33+ myeloid cells, CD33+CD11+ myeloid cells, total MDSCs (CD33+CD11+HLA-DR-/low), monocytic MDSCs, and granulocytic MDSCs decreased significantly. The regulatory T cells and B cells, two important suppressive lymphocyte subpopulations, also decreased. On the other hand, the levels of CD3+ T cells, total B cells, central memory CD4+ T cells, and pro-inflammatory cytokines (including Interleukin [IL]-1β, IL-6, IL-2, IL-5, and IL-8) increased significantly after GP administration. Besides, GP chemotherapy did not weaken the cytotoxic activity and proliferative capacity of T cells.
Our results showed the immune modulation effect of GP induction chemotherapy in locoregionally advanced NPC, providing a solid basis for its combination with immunotherapy.
研究试图在局部晚期鼻咽癌（NPC）患者中，将免疫疗法加入吉西他滨和顺铂（GP）诱导化疗的标准疗法中。然而，免疫系统对 GP 的反应如何尚不清楚。
我们检测了接受 GP 治疗的 NPC 患者循环免疫细胞和血浆细胞因子的动态变化。
GP 给药后，抑制性髓系细胞（包括 CD11b+CD14+单核细胞、CD33+髓系细胞、CD33+CD11+髓系细胞、总髓源性抑制细胞（CD33+CD11+HLA-DR-/低）、单核细胞来源的髓源性抑制细胞和粒细胞来源的髓源性抑制细胞）显著减少。两种重要的抑制性淋巴细胞亚群调节性 T 细胞和 B 细胞也减少了。另一方面，GP 化疗后 CD3+T 细胞、总 B 细胞、中央记忆 CD4+T 细胞和促炎细胞因子（包括白细胞介素[IL]-1β、IL-6、IL-2、IL-5 和 IL-8）水平显著升高。此外，GP 化疗并未削弱 T 细胞的细胞毒性活性和增殖能力。
我们的结果显示了 GP 诱导化疗对局部晚期 NPC 的免疫调节作用，为其与免疫疗法联合应用提供了坚实的基础。
